Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$18.38 USD
+0.13 (0.71%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.39 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FMS 18.38 +0.13(0.71%)
Will FMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FMS
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
Can These 3 Medical Device Stocks Hit Earnings This Season?
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Fresenius (FMS) is a Strong Value Stock
Other News for FMS
Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Sell from J.P. Morgan
GLOBAL BROKER RATINGS: Citi says 'buy' Glencore; Deutsche cuts Evotec
European exporters with stretched valuations - JPM
GLOBAL BROKER RATINGS: LBBW raises BASF; Goldman Sachs cuts Heidelberg